Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Innoviva's price to book ratio was 1.1× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 1.1× to 7.8×, with a median of 2.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.1× | −0.6 |
| 2025 | Apr 30, 2025 | 1.7× | +0.3 |
| 2023 | Apr 28, 2023 | 1.4× | −0.0 |
| 2022 | Dec 30, 2022 | 1.4× | −1.5 |
| 2021 | Dec 31, 2021 | 3.0× | +0.4 |
| 2020 | Dec 31, 2020 | 2.6× | −2.8 |
| 2019 | Dec 31, 2019 | 5.4× | −3.9 |
| 2014 | Jul 31, 2014 | 9.3× | −2.7 |
| 2013 | Dec 31, 2013 | 11.9× | −0.6 |
| 2012 | Dec 31, 2012 | 12.6× | – |
See a number that looks wrong?